公开(公告)号：US10385399B2

公开(公告)日：2019-08-20

申请号：US14114496

申请日：2012-04-30

Applicant: Jens Overgaard ,  Brita Singers Sorensen ,  Jan Alsner ,  Carsten Wiuf ,  Marianne Nordsmark ,  Kasper Toustrup

Inventor： Jens Overgaard ,  Brita Singers Sorensen ,  Jan Alsner ,  Carsten Wiuf ,  Marianne Nordsmark ,  Kasper Toustrup

IPC: C12Q1/6886 ,  A61K31/5377 ,  A61K45/06 ,  A61N5/10 ,  G01N33/49

Abstract: The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.

公开(公告)号：US20100322939A1

公开(公告)日：2010-12-23

申请号：US12664258

申请日：2008-06-17

Applicant: Jens Overgaard

Inventor： Jens Overgaard

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K39/39558 ,  A61K41/0038 ,  A61K2039/545 ,  A61N5/10 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  A61K2300/00

Abstract: The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent.

Abstract translation: 本发明涉及一种治疗EGFR相关肿瘤的方法，包括向有需要的个体施用抗EGFR抗体与放射治疗和放射增敏剂的组合。 在一个实施方案中，治疗还包括施用化学治疗剂。

公开(公告)号：US20120040004A1

公开(公告)日：2012-02-16

申请号：US13146498

申请日：2010-01-28

Applicant: Kenneth Alan Howard ,  Jørgen Kjems ,  Isabel Nawroth ,  Jan Alsner ,  Jens Overgaard ,  Flemming Besenbacher

Inventor： Kenneth Alan Howard ,  Jørgen Kjems ,  Isabel Nawroth ,  Jan Alsner ,  Jens Overgaard ,  Flemming Besenbacher

IPC: A61K31/713 ,  A61P43/00 ,  A61K9/14 ,  B82Y5/00

CPC classification number: C12N15/113 ,  A61K9/5161 ,  C12N15/111 ,  C12N2310/14 ,  C12N2320/32

Abstract: The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha.

Abstract translation: 本发明涉及使用TNF-α拮抗作用来治疗或预防辐射诱导的纤维化。 优选地，通过直接结合或抑制合成来拮抗TNF-α。 在优选的实施方案中，本发明包括腹膜内施用壳聚糖-siRNA纳米颗粒，其中siRNA靶向编码TNF-α的mRNA。

公开(公告)号：US20150159218A1

公开(公告)日：2015-06-11

申请号：US14114496

申请日：2012-04-30

Applicant: Jens Overgaard ,  Brita Singers Sorensen ,  Jan Alsner ,  Carsten Wiuf ,  Marianne Nordsmark ,  Kasper Toustrup

Inventor： Jens Overgaard ,  Brita Singers Sorensen ,  Jan Alsner ,  Carsten Wiuf ,  Marianne Nordsmark ,  Kasper Toustrup

IPC: C12Q1/68 ,  A61N5/10 ,  G01N33/49 ,  A61K31/5377 ,  A61K45/06

CPC classification number: C12Q1/6886 ,  A61K31/5377 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1098 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/4925

Abstract: The present invention provides a method for determining the oxygen status of a cancer of an individual. The method comprise determining the transcriptional expression level of ADM (SEQ ID No:1), and/or at least one gene selected from ANKRD37 (SEQ ID NO.: 3), P4HA2 (SEQ ID NO.: 12), NDRG1 (SEQ ID NO: 10), SLC2A1 (SEQ ID NO:15), P4HA1 (SEQ ID NO.: 11), LOX (SEQ ID NO.: 9), C3orf28 (SEQ ID NO.: 6), BNIP3L (SEQ ID NO.: 5), BNIP3 (SEQ ID NO.:4), EGLN3 (SEQ ID NO.: 7), PDK1 (SEQ ID NO.: 13), PFKFB3 (SEQ ID NO.: 14), KCTD11 (SEQ ID NO.: 8), and/or ALDOA (SEQ ID NO.: 2), in a cancer sample. The transcriptional level is then correlated to the transcriptional level to at least one reference gene, and oxygen status 10 is then evaluated by comparing the correlated transcription level with a predetermined reference sample comprising cancer cells characterized by a high oxygen level.

Abstract translation: 本发明提供了确定个体癌症的氧状态的方法。 该方法包括确定ADM（SEQ ID No：1）和/或至少一种选自ANKRD37（SEQ ID NO：3），P4HA2（SEQ ID NO：12），NDRG1（SEQ ID NO：1）的基因的转录表达水平 SEQ ID NO：10），SLC2A1（SEQ ID NO：15），P4HA1（SEQ ID NO：11），LOX（SEQ ID NO：9），C3orf28（SEQ ID NO：6），BNIP3L ：5），BNIP3（SEQ ID NO：4），EGLN3（SEQ ID NO：7），PDK1（SEQ ID NO：13），PFKFB3（SEQ ID NO：14），KCTD11（SEQ ID NO： 。：8）和/或ALDOA（SEQ ID NO：2）。 然后将转录水平与至少一个参考基因的转录水平相关，然后通过将相关转录水平与包含以高氧水平为特征的癌细胞的预定参考样品进行比较来评估氧状态10。